Leticia F. Terra

Leticia F. Terra

Auto-generated profile, based on publicly available information

Leticia F. Terra

NUCEL, University of São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LGLuciana R Gomes
Luciana R Gomes
LTLetícia F Terra
Letícia F Terra
RWRosângela Am Wailemann
Rosângela Am Wailemann
LLLeticia Labriola
Leticia Labriola
MSMari Sogayar
Mari Sogayar
Background: Metastasis is the main factor responsible for death in breast cancer patients. Matrix metalloproteinases (MMPs) and their inhibitors, known as tissue inhibitors of MMPs (TIMPs), and the membrane-associated MMP inhibitor (RECK), are essential for the metastatic process. We have previously shown a positive correlation between MMPs and their inhibitors expression during breast cancer progression; however, the molecular mechanisms underlying this coordinate regulation remain unknown. In this report, we investigated whether TGF-β1 could be a common regulator for MMPs, TIMPs and RECK in human breast cancer cell models. Methods: The mRNA expression levels of TGF-β isoforms and their receptors were analyzed by qRT-PCR in a panel of five human breast cancer cell lines displaying different degrees of invasiveness and metastatic potential. The highly invasive MDA-MB-231 cell line was treated with different concentrations of recombinant TGF-β1 and also with pharmacological inhibitors of p38 MAPK and ERK1/2. The migratory and invasive potential of these treated cells were examined in vitro by transwell assays. Results: In general, TGF-β2, TβRI and TβRII are over-expressed in more aggressive cells, except for TβRI, which was also highly expressed in ZR-75-1 cells. In addition, TGF-β1-treated MDA-MB-231 cells presented significantly increased mRNA expression of MMP-2, MMP-9, MMP-14, TIMP-2 and RECK. TGF-β1 also increased TIMP-2, MMP-2 and MMP-9 protein levels but downregulated RECK expression. Furthermore, we analyzed the involvement of p38 MAPK and ERK1/2, representing two well established Smad-independent pathways, in the proposed mechanism. Inhibition of p38MAPK blocked TGF-β1-increased mRNA expression of all MMPs and MMP inhibitors analyzed, and prevented TGF-β1 upregulation of TIMP-2 and MMP-2 proteins. Moreover, ERK1/2 inhibition increased RECK and prevented the TGF-β1 induction of pro-MMP-9 and TIMP-2 proteins. TGF-β1-enhanced migration and invasion capacities were blocked by p38MAPK, ERK1/2 and MMP inhibitors. Conclusion: Altogether, our results support that TGF-β1 modulates the mRNA and protein levels of MMPs (MMP-2 and MMP-9) as much as their inhibitors (TIMP-2 and RECK). Therefore, this cytokine plays a crucial role in breast cancer progression by modulating key elements of ECM homeostasis control. Thus, although the complexity of this signaling network, TGF-β1 still remains a promising target for breast cancer treatment.

15 March 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ASAncely dos Santos
Ancely dos Santos
LTLetícia F. Terra
Letícia F. Terra
RMRosangela A Wailemann Mansano
Rosangela A Wailemann Mansano
TOTalita C. Oliveira
Talita C. Oliveira
VGVinicius de Morais Gomes
Vinicius de Morais Gomes
LLLeticia Labriola
Leticia Labriola
Breast cancer is the main cause of mortality among women. The disease presents high recurrence mainly due to incomplete efficacy of primary treatment in killing all cancer cells. Photodynamic therapy (PDT), an approach that causes tissue destruction by visible light in the presence of a photosensitizer (Ps) and oxygen, appears as a promising alternative therapy that could be used adjunct to chemotherapy and surgery for curing cancer. However, the efficacy of PDT to treat breast tumours as well as the molecular mechanisms that lead to cell death remain unclear. In this study, we assessed the cell-killing potential of PDT using methylene blue (MB-PDT) in three breast epithelial cell lines that represent non-malignant conditions and different molecular subtypes of breast tumours. Cells were incubated in the absence or presence of MB and irradiated or not at 640 nm with 4.5 J/cm2. We used a combination of imaging and biochemistry approaches to assess the involvement of classical autophagic and apoptotic pathways in mediating the cell-deletion induced by MB-PDT. The role of these pathways was investigated using specific inhibitors, activators and gene silencing. We observed that MB-PDT differentially induces massive cell death of tumour cells. Non-malignant cells were significantly more resistant to the therapy compared to malignant cells. Morphological and biochemical analysis of dying cells pointed to alternative mechanisms rather than classical apoptosis. MB-PDT-induced autophagy modulated cell viability depending on the cell model used. However, impairment of one of these pathways did not prevent the fatal destination of MB-PDT treated cells. Additionally, when using a physiological 3D culture model that recapitulates relevant features of normal and tumorous breast tissue morphology, we found that MB-PDT differential action in killing tumour cells was even higher than what was detected in 2D cultures. Finally, our observations underscore the potential of MB-PDT as a highly efficient strategy which could use as a powerful adjunct therapy to surgery of breast tumours, and possibly other types of tumours, to safely increase the eradication rate of microscopic residual disease and thus minimizing the chance of both local and metastatic recurrence.

1 November 2011 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
LGL. R. Gomes
L. R. Gomes
LTL. F. Terra
L. F. Terra
MSMari Sogayar
Mari Sogayar
LLL. Labriola
L. Labriola
During the past few years, Epithelial-Mesenchymal Transition (EMT) has emerged as one of the most hot spots in clinical research. Its existence in human tumors can form the basis for explaining characteristics of cancer progression and metastasis, as well as certain cases of drug resistance and relapses after treatment. These cellular responses are tightly regulated by intracellular signaling pathways evoked by humoral factors that include growth factors, chemokines and cytokines. Indeed, several gene regulatory programs known to promote EMT during development have recently been discovered to play key roles in cancer progression. A deeper understanding of the cellular and molecular basis of these different programs should aid in both the development of better diagnosis methods, as well as of specific treatments for invasive cancer. In this review we set out to summarize recent novel insights into the molecular players underlying EMT and its relation with cancer progression and metastasis.

11 March 2011 in Diabetologia
Verified
Journal Article
Closed access
PDF file
LTL. F. Terra
L. F. Terra
Miguel Miguel Garay MalpartidaMiguel Miguel Garay Malpartida
Miguel Miguel Garay Malpartida
RWR. A. M. Wailemann
R. A. M. Wailemann
MSMari Sogayar
Mari Sogayar
LLLeticia Labriola
Leticia Labriola

3 December 2015 in Diabetologia
Verified
Journal Article
Closed access
PDF file
KMKira Meyerovich
Kira Meyerovich
MFMakiko Fukaya
Makiko Fukaya
LTLeticia F. Terra
Leticia F. Terra
Fernanda OrtisFernanda Ortis
Fernanda Ortis
DEDecio L. Eizirik
Decio L. Eizirik
ACAlessandra Kupper Cardozo
Alessandra Kupper Cardozo

1 April 2019 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LTLetícia F. Terra
Letícia F. Terra
RMRosangela A Wailemann Mansano
Rosangela A Wailemann Mansano
ASAncély F. dos Santos
Ancély F. dos Santos
VGVinicius de Morais Gomes
Vinicius de Morais Gomes
RSRailmara P. Silva
Railmara P. Silva
LLLeticia Labriola
Leticia Labriola